23
total announcements
ASTRAZEN.BO · 15 min delayed
Key Stats · Yahoo Finance · as of 21 Oct 2026
Market Cap
₹15,108 Cr
P/E (TTM)
89.1
EPS (TTM)
₹67.85
52W Low
₹5,660.00
52W High
₹9,850.00
Dividend Yield
0.60%
Beta
0.23
Price / Book
17.3
Debt / Equity
12.7
Revenue (TTM)
₹2,432 Cr
Gross Margin
36.83%
Operating Margin
6.40%
AstraZeneca Pharma India Ltd
AstraZeneca Pharma India Ltd has received permission from the Central Drugs Standard Control Organization to import and market Trastuzumab Deruxtecan 100mg/5mL lyophilized powder for concentrate for solution for infusion (Brand name: Enhertu) for an additional indication in India.
AstraZeneca Pharma India Ltd
AstraZeneca Pharma India Ltd has announced that it will deduct tax at source on the final dividend for the financial year 2025-26, as per the Finance Act 2020. The dividend will be paid after deducting tax at source under section 393 of the Income Tax Act, 2025. Resident shareholders who do not have a PAN or have an invalid PAN will have 20% tax deducted, while those who provide a self-attested copy of PAN and meet other conditions may be exempt from tax. Non-resident shareholders will have 20% tax deducted, unless they provide a tax treaty benefit certificate.
AstraZeneca Pharma India Ltd
AstraZeneca Pharma India Ltd has announced the resignation of its Chief Financial Officer (CFO), Ms. Bhavana Agrawal, effective August 31, 2026, due to her appointment to a regional role within the AstraZeneca Group.